CB-183: Phase II started

Cubist began a double-blind, dose-ranging, U.S. and Canadian Phase II trial to evaluate 125 and 250 mg oral CB-183,315 given twice daily vs. 125 mg oral Vancocin vancomycin given four times daily for...